title: New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia.
abstract: Chronic lymphocytic leukemia (CLL) is characterized by the clonal proliferation and accumulation of mature B lymphocytes. CLL cells show an antiapoptotic profile, suggesting the important role of apoptosis inhibition in the disease development. However, there is some population of proliferating CLL cells, which may also play a role in progression of the disease. There are several newer, biological prognostic factors in CLL. Currently, cytogenetic abnormalities with different prognostic values seem to be the most biologically relevant. During the last decades, the treatment of CLL has been significantly changed. Different strategies such as monotherapy with chlorambucil and purine nucleoside analogues (PNA) used alone or in combination with cyclophosphamide have been introduced. Most recently, immunochemotherapy with anti-CD20 monoclonal antibody, rituximab, combined with fludarabine and cyclophosphamide, became a gold standard of first-line treatment in eligible CLL patients. Currently, new treatment strategies including new monoclonal antibodies, bendamustine, lenalidomide, or inhibitors of several cell signaling pathways are under clinical studies in resistant/relapsed CLL patients. Moreover, allogeneic stem cell transplantation has to be considered, especially in younger high risk patients, for example, those who are resistant to PNA or those with 17p deletion. In this paper, we present the most important recent advances in CLL biology and treatment.
authors.affiliation: Department of Experimental Hematology, Medical University of Lodz, Ciolkowskiego 2 Street, 93-510 Lodz, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Smolewski
authors.forename: Magdalena
authors.initials: M
authors.lastname: Witkowska
authors.forename: Anna
authors.initials: A
authors.lastname: Korycka-Wołowiec
references.citation: N Engl J Med. 2000 Dec 14;343(24):1750-7
references.pmid: 11114313
references.citation: Leukemia. 2008 Nov;22(11):2048-53
references.pmid: 18754025
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Eur J Haematol. 2007 Aug;79(2):107-13
references.pmid: 17635235
references.citation: Blood. 2006 Feb 1;107(3):885-91
references.pmid: 16219797
references.citation: Blood. 1999 Jul 15;94(2):448-54
references.pmid: 10397712
references.citation: Nat Rev Clin Oncol. 2011 Jan;8(1):38-47
references.pmid: 20956983
references.citation: Lancet. 2010 Oct 2;376(9747):1164-74
references.pmid: 20888994
references.citation: Blood. 2007 Jan 15;109(2):405-11
references.pmid: 17008537
references.citation: Leuk Lymphoma. 2012 Mar;53(3):424-9
references.pmid: 21919823
references.citation: Leukemia. 2007 Jan;21(1):12-7
references.pmid: 17109028
references.citation: N Engl J Med. 1998 May 21;338(21):1506-14
references.pmid: 9593789
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1749-55
references.pmid: 20194866
references.citation: Leukemia. 2013 Apr;27(5):1172-4
references.pmid: 22936013
references.citation: Ann Diagn Pathol. 2007 Oct;11(5):363-89
references.pmid: 17870025
references.citation: N Engl J Med. 2000 Dec 28;343(26):1910-6
references.pmid: 11136261
references.citation: Curr Opin Mol Ther. 2008 Jun;10(3):294-309
references.pmid: 18535937
references.citation: Cancer. 1981 Jul 1;48(1):198-206
references.pmid: 7237385
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4378-84
references.pmid: 19652068
references.citation: Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S132-8
references.pmid: 22226097
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1175-81
references.pmid: 21189385
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6012-8
references.pmid: 19826119
references.citation: Blood. 2011 Aug 25;118(8):2085-93
references.pmid: 21670470
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1756-65
references.pmid: 20194844
references.citation: Semin Cancer Biol. 2010 Dec;20(6):377-83
references.pmid: 21029776
references.citation: N Engl J Med. 2003 May 1;348(18):1764-75
references.pmid: 12724482
references.citation: J Cancer Res Clin Oncol. 2012 Jun;138(6):1011-7
references.pmid: 22362302
references.citation: Expert Opin Biol Ther. 2012 May;12(5):543-5
references.pmid: 22428785
references.citation: J Clin Oncol. 2012 Feb 10;30(5):488-96
references.pmid: 22184378
references.citation: Blood. 2009 Jan 8;113(2):299-305
references.pmid: 18931344
references.citation: Blood. 2009 Oct 15;114(16):3382-91
references.pmid: 19605849
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5208-12
references.pmid: 19738118
references.citation: Am J Hematol. 2007 Dec;82(12):1063-70
references.pmid: 17654680
references.citation: Blood. 2006 Jul 15;108(2):473-9
references.pmid: 16551966
references.citation: J Clin Oncol. 2007 Dec 10;25(35):5616-23
references.pmid: 17984186
references.citation: Ann Hematol. 2003 Dec;82(12):759-65
references.pmid: 14551737
references.citation: Blood. 2011 Sep 29;118(13):3489-98
references.pmid: 21725050
references.citation: Blood. 1999 Sep 15;94(6):1848-54
references.pmid: 10477713
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1863-9
references.pmid: 20212251